STAT+: Eczema drug from Nektar Therapeutics maintains skin responses in one-year study
STAT [Unofficial]
February 10, 2026
An eczema drug from Nektar Therapeutics maintained skin responses in a one-year study, meeting and in some cases exceeding investor expectations.
Discussion in the ATmosphere